Animal experimental investigation on the efficacy of antibiotic therapy with linezolid, vancomycin, cotrimoxazole, and rifampin in treatment of periprosthetic knee joint infections by MRSA.

Antibiotics monotherapy Combination antibiotics therapies Infection of the artificial joint Linezolid and rifampin MRSA Rifampin or cotrimoxazole Vancomycin antibiotic therapies antibiotics clinical studies femur joint infections methicillin-resistant Staphylococcus aureus (MRSA) rat model rifampicin strains vancomycin

Journal

Bone & joint research
ISSN: 2046-3758
Titre abrégé: Bone Joint Res
Pays: England
ID NLM: 101586057

Informations de publication

Date de publication:
Mar 2022
Historique:
entrez: 1 3 2022
pubmed: 2 3 2022
medline: 2 3 2022
Statut: ppublish

Résumé

Periprosthetic joint infections (PJIs) are rare, but represent a great burden for the patient. In addition, the incidence of methicillin-resistant For this purpose, sterilized steel implants were implanted into the femur of 77 rats. The metal devices were inoculated with suspensions of two different MRSA strains. The animals were divided into groups and treated with vancomycin, linezolid, cotrimoxazole, or rifampin as monotherapy, or with combination of antibiotics over a period of 14 days. After a two-day antibiotic-free interval, the implant was explanted, and bone, muscle, and periarticular tissue were microbiologically analyzed. Vancomycin and linezolid were able to significantly (p < 0.05) reduce the MRSA bacterial count at implants. No significant effect was found at the bone. Rifampin was the only monotherapy that significantly reduced the bacterial count on implant and bone. The combination with vancomycin or linezolid showed significant efficacy. Treatment with cotrimoxazole alone did not achieve a significant bacterial count reduction. The combination of linezolid plus rifampin was significantly more effective on implant and bone than the control group in both trials. Although rifampicin is effective as a monotherapy, it should not be used because of the high rate of resistance development. Our animal experiments showed the great importance of combination antibiotic therapies. In the future, investigations with higher case numbers, varied bacterial concentrations, and changes in individual drug dosages will be necessary to be able to draw an exact comparison, possibly within a clinical trial. Cite this article:

Identifiants

pubmed: 35227086
doi: 10.1302/2046-3758.113.BJR-2021-0268.R1
pmc: PMC8962855
doi:

Types de publication

Journal Article

Langues

eng

Pagination

143-151

Références

Antimicrob Agents Chemother. 2002 Apr;46(4):1122-4
pubmed: 11897604
Int J Artif Organs. 2011 Sep;34(9):947-56
pubmed: 22094577
Clin Microbiol Infect. 2009 Dec;15(12):1163-9
pubmed: 19438638
Int J Antimicrob Agents. 2006 May;27(5):444-8
pubmed: 16621461
Antimicrob Agents Chemother. 2009 Jul;53(7):2719-24
pubmed: 19364845
Bone Joint Res. 2020 May 16;9(2):79-81
pubmed: 32435459
Clin Orthop Relat Res. 2007 Aug;461:48-53
pubmed: 17534195
Bone Joint Res. 2019 Dec 3;8(11):526-534
pubmed: 31832172
Clin Microbiol Rev. 2014 Apr;27(2):302-45
pubmed: 24696437
Bone Joint Res. 2020 Dec;9(12):848-856
pubmed: 33275031
J Orthop Res. 2004 Nov;22(6):1351-7
pubmed: 15475220
Bone Joint Res. 2019 Jun 05;8(5):189-198
pubmed: 31214331
J Clin Microbiol. 1992 Aug;30(8):2058-63
pubmed: 1500513
Biol Trace Elem Res. 2016 Oct;173(2):384-9
pubmed: 26961291
Bone Joint Res. 2019 Jun 5;8(5):199-206
pubmed: 31214332
Bone Joint Res. 2020 Nov;9(11):778-788
pubmed: 33135425
Antimicrob Agents Chemother. 2010 Feb;54(2):950-2
pubmed: 19933800
Pathologe. 2011 May;32(3):210-9
pubmed: 21526399
Drug Des Devel Ther. 2017 Jun 14;11:1729-1736
pubmed: 28652709
Eur Rev Med Pharmacol Sci. 2017 Oct;21(17):3974-3979
pubmed: 28975963
Bone Joint Res. 2020 Jun 8;9(5):211-218
pubmed: 32566142
Antimicrob Agents Chemother. 2011 Mar;55(3):1182-6
pubmed: 21189340
J Orthop Surg (Hong Kong). 2018 Jan-Apr;26(1):2309499017754093
pubmed: 29382296
Clin Microbiol Infect. 2005 Jul;11 Suppl 4:33-42
pubmed: 15997484
Antimicrob Agents Chemother. 2009 Mar;53(3):1142-8
pubmed: 19075065
Antimicrob Agents Chemother. 2010 Dec;54(12):5251-6
pubmed: 20921321
J Clin Invest. 1984 Apr;73(4):1191-200
pubmed: 6323536
Health Technol Assess. 2019 Jun;23(32):1-216
pubmed: 31287051
Clin Orthop Relat Res. 2004 Oct;(427):67-71
pubmed: 15552139
Swiss Med Wkly. 2005 Apr 30;135(17-18):243-51
pubmed: 15965826
Bone Joint Res. 2020 Dec;9(12):870-872
pubmed: 33307769
Bone Joint Res. 2020 May 16;9(2):77-78
pubmed: 32435458
Bone Joint Res. 2019 Dec 3;8(11):570-572
pubmed: 31832177
APMIS. 2017 Jan;125(1):38-45
pubmed: 27704604
PLoS One. 2016 Jun 22;11(6):e0157626
pubmed: 27333300
Clin Microbiol Infect. 2011 Jul;17(7):1098-100
pubmed: 21595792
Clin Orthop Relat Res. 2001 Nov;(392):15-23
pubmed: 11716377

Auteurs

Julia Goetz (J)

Department of Orthopaedic Surgery, University Hospital Regensburg - Asklepios Bad Abbach, Regensburg, Germany.

Verena Keyssner (V)

Department of Orthopaedic Surgery, University Hospital Regensburg - Asklepios Bad Abbach, Regensburg, Germany.

Frank Hanses (F)

Department of Infectology, University Hospital Regensburg, Regensburg, Germany.

Felix Greimel (F)

Department of Orthopaedic Surgery, University Hospital Regensburg - Asklepios Bad Abbach, Regensburg, Germany.

Franziska Leiß (F)

Department of Orthopaedic Surgery, University Hospital Regensburg - Asklepios Bad Abbach, Regensburg, Germany.

Timo Schwarz (T)

Department of Orthopaedic Surgery, University Hospital Regensburg - Asklepios Bad Abbach, Regensburg, Germany.

Hans-Robert Springorum (HR)

Department of Orthopaedic Surgery, University Hospital Regensburg - Asklepios Bad Abbach, Regensburg, Germany.

Joachim Grifka (J)

Department of Orthopaedic Surgery, University Hospital Regensburg - Asklepios Bad Abbach, Regensburg, Germany.

Jens Schaumburger (J)

Department of Orthopaedic Surgery, University Hospital Regensburg - Asklepios Bad Abbach, Regensburg, Germany.

Classifications MeSH